SmallCapReview.com is a leading small cap stock information site since 1999, to register for the free SmallCapReview newsletter visit http://www.smallcapreview.com.
Star Bulk Carriers (Nasdaq: SBLK) $5.37. Announced Monday after market close its unaudited financial and operating results for the three month period ended March 31, 2009. For the first quarter of 2009, net income was $22.5 million versus net income of $16.7 million for the first quarter of 2008, an increase of approximately 34%. For the first quarter of 2009, total revenue was $45.1 million versus total revenue of $41.7 million for the first quarter of 2008, an increase of approximately 8%. Earnings per share, basic and diluted for the first quarter of 2009 were $0.37 based on a weighted average of 60,390,219 shares outstanding, basic and diluted. Earnings per share, basic and diluted for the first quarter of 2009 were $0.16, excluding non-cash items. EBITDA for the first quarter of 2009 was $40.8 million. Adjusted EBITDA for the same period excluding all the above was $27.8 million. Star Bulk is a current focus stock at SmallCapReview.com.
What They Do: Star Bulk is a global shipping company providing worldwide seaborne transportation solutions in the dry bulk sector.
Sanofi-aventis (NYSE: SNY) and Exelixis (Nasdaq: EXEL) $4.51. Today announced a global license agreement for XL147 and XL765 and a broad collaboration for the discovery of inhibitors of phosphoinositide-3 kinase (PI3K) for the treatment of cancer. Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival and resistance to chemotherapy and radiotherapy. Under the license, sanofi-aventis will have a worldwide exclusive license to XL147 and XL765, which are currently in phase 1 and phase 1b/2 clinical trials, and will have sole responsibility for all subsequent clinical, regulatory, commercial and manufacturing activities. Exelixis will participate in conducting ongoing and potential future clinical trials and manufacturing activities.
Under the discovery collaboration, Exelixis and sanofi-aventis will combine efforts in establishing several pre-clinical PI3K programs and jointly share responsibility for research and preclinical activities related to isoform-selective inhibitors of PI3K.
What They Do: Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases.
SmartHeat (Nasdaq: HEAT) $7.00. Today announced that the Company has won a $3 million contract with a Chinese municipality to supply SmartHeat's energy savings products to the Inner Mongolia regions in China. The contract was won by SmartHeat in a bidding process against its local and international competitors. SmartHeat believes its superior technology and high level of customer service were instrumental in securing this order. SmartHeat's winning bid reflects the Company's technical advantage and exceptional after sales services despite the fact that SmartHeat's product pricing is among the highest in the marketplace, allowing it to maintain healthy margins in a competitive environment.
What They Do: SmartHeat is a market leader in China's clean technology energy savings industry.
About SmallCapReview
Copyright SmallCapReview. SmallCapReview.com has been a leading site for news on small-cap stocks since 1999. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select small-cap stocks, to register visit http://www.smallcapreview.com/.
